Buscar





Buscar





Mercado
/
Acciones
/
nasdaq-exas
/

Exact Sciences Corp

EXAS

Añadir a la lista de seguimiento

104.910USD

0.0000.00%

Horarios del mercado （ET）Cotizaciones retrasadas 15 min

20.03BCap. mercado

PérdidaP/E TTM



Exact Sciences Corp

104.910

0.0000.00%

Descripción general Finanzas Discusiones Análisis Compañía

Descripción general

Finanzas

Discusiones

Análisis

Compañía

Más Datos de Exact Sciences Corp Compañía

Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Información de Exact Sciences Corp



Símbolo de cotizaciónEXAS

Nombre de la empresaExact Sciences Corp

Fecha de salida a bolsaJan 30, 2001

Director ejecutivoConroy (Kevin T)

Número de empleados6900

Tipo de seguridadOrdinary Share

Fin del año fiscalJan 30

Dirección5505 Endeavor Lane

CiudadMADISON

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal53719

Teléfono16082845700

Sitio Webhttps://www.exactsciences.com/

Símbolo de cotizaciónEXAS

Fecha de salida a bolsaJan 30, 2001

Director ejecutivoConroy (Kevin T)

Ejecutivos de Exact Sciences Corp



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Kevin T. Conroy

Chairman of the Board, President, Chief Executive Officer

279.16K

-457.95%

Mr. Daniel J. (Dan) Levangie

Independent Director

34.31K

+15.73%

Ms. Shacey Petrovic

Independent Director

7.09K

-307.32%

Mr. Brian Baranick

Executive Vice President, General Manager - Precision Oncology

670.00

-15503.58%

Mr. Aaron Bloomer

Chief Financial Officer, Executive Vice President

212.00

-23003.77%

Ms. Katherine S. (Kay) Zanotti

Independent Director

-100.00%

Mr. James E. Doyle

Lead Independent Director

Mr. D. Scott Coward

Director

Mr. Jacob (Jake) Orville

Executive Vice President, General Manager - Screening

Mr. Paul Clancy

Independent Director

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Kevin T. Conroy

Chairman of the Board, President, Chief Executive Officer

279.16K

-457.95%

Mr. Daniel J. (Dan) Levangie

Independent Director

34.31K

+15.73%

Ms. Shacey Petrovic

Independent Director

7.09K

-307.32%

Mr. Brian Baranick

Executive Vice President, General Manager - Precision Oncology

670.00

-15503.58%

Mr. Aaron Bloomer

Chief Financial Officer, Executive Vice President

212.00

-23003.77%

Ms. Katherine S. (Kay) Zanotti

Independent Director

-100.00%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de abr

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Commercial

1.52B

46.79%

Medicare Parts B & C

1.15B

35.46%

Other

352.22M

10.85%

International

223.84M

6.89%

Por regiónUSD

Nombre

Ganancia

Proporción

United States (Country)

3.02B

93.11%

Outside of united states

223.84M

6.89%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Commercial

1.52B

46.79%

Medicare Parts B & C

1.15B

35.46%

Other

352.22M

10.85%

International

223.84M

6.89%

Estadísticas de accionistas

Actualizado: dom., 10 de may

Accionistas

Tipos de accionistas

Accionistas

Proporción

HBK Investments, L.P.

4.01%

BlackRock Institutional Trust Company, N.A.

3.81%

Pentwater Capital Management LP

3.80%

BlackRock Financial Management, Inc.

2.62%

State Street Investment Management (US)

2.19%

Otro

83.58%

Accionistas

Proporción

HBK Investments, L.P.

4.01%

BlackRock Institutional Trust Company, N.A.

3.81%

Pentwater Capital Management LP

3.80%

BlackRock Financial Management, Inc.

2.62%

State Street Investment Management (US)

2.19%

Otro

83.58%

Tipos de accionistas

Accionistas

Proporción

Hedge Fund

25.83%

Investment Advisor/Hedge Fund

21.00%

Investment Advisor

13.69%

Research Firm

3.11%

Sovereign Wealth Fund

1.80%

Private Equity

0.82%

Pension Fund

0.79%

Bank and Trust

0.60%

Individual Investor

0.21%

Otro

32.16%

Participación institucional



Actualizado: dom., 5 de abr

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2026Q1

1452

147.12M

77.07%

-48.70M

2025Q4

1286

180.92M

105.49%

2025Q3

1352

180.95M

106.13%

-112.86K

2025Q2

1416

180.92M

107.16%

-6.42M

2025Q1

1400

186.11M

105.23%

-12.34M

2024Q4

1391

186.68M

107.44%

-1.15M

2024Q3

1351

188.95M

104.99%

+4.63M

2024Q2

1335

183.23M

95.81%

+15.73M

2024Q1

1330

166.64M

95.05%

-5.91M

2023Q4

1339

163.38M

96.52%

-2.83M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

HBK Investments, L.P.

7.65M

4.01%

+7.65M

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

7.28M

3.81%

+121.88K

+1.70%

Dec 31, 2025

Pentwater Capital Management LP

7.25M

3.8%

+7.25M

Dec 31, 2025

BlackRock Financial Management, Inc.

5.00M

2.62%

+3.56M

+247.46%

Dec 31, 2025

State Street Investment Management (US)

4.18M

2.19%

-1.01M

-19.48%

Dec 31, 2025

Balyasny Asset Management LP

4.09M

2.14%

+3.24M

+382.56%

Dec 31, 2025

Millennium Management LLC

3.44M

1.8%

+1.22M

+55.20%

Dec 31, 2025

Norges Bank Investment Management (NBIM)

3.43M

1.8%

+2.52M

+276.89%

Dec 31, 2025

Geode Capital Management, L.L.C.

3.33M

1.75%

+19.75K

+0.60%

Dec 31, 2025

MFS Investment Management

2.72M

1.42%

-1.10M

-28.83%

Dec 31, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

First Trust Nasdaq Lux Digi Health Solutions ETF

4.48%

Invesco Biotechnology & Genome ETF

3.72%

First Trust NYSE Arca Biotechnology Index Fund

3.72%

Alger Mid Cap 40 ETF

3.61%

Clough Select Equity ETF

3.13%

Clough Hedged Equity ETF

2.78%

iShares Health Innovation Active ETF

2.72%

State Street SPDR S&P Biotech ETF

2.32%

First Trust Indxx Medical Devices ETF

2.22%

ROBO Global Healthcare Technology & Innovation ETF

2.03%

First Trust Nasdaq Lux Digi Health Solutions ETF

Proporción4.48%

Invesco Biotechnology & Genome ETF

Proporción3.72%

First Trust NYSE Arca Biotechnology Index Fund

Proporción3.72%

Alger Mid Cap 40 ETF

Proporción3.61%

Clough Select Equity ETF

Proporción3.13%

Clough Hedged Equity ETF

Proporción2.78%

iShares Health Innovation Active ETF

Proporción2.72%

State Street SPDR S&P Biotech ETF

Proporción2.32%

First Trust Indxx Medical Devices ETF

Proporción2.22%

ROBO Global Healthcare Technology & Innovation ETF

Proporción2.03%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

KeyAI

